Join the High Cholesterol - Familial Heterozygous group to help and get support from people like you.
High Cholesterol - Familial Heterozygous News
Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous
Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
FRIDAY, March 28, 2025 – Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy, according to...
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
FRIDAY, Feb. 21, 2025 – Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized phospholipids (OxPL) on...
Cholesterol Changes in Seniors Linked to Brain Health
THURSDAY, Jan. 30, 2025 – Seniors whose cholesterol levels spike and plummet year-to-year could be at increased risk of dementia and failing brain health, a new study suggests. Those whose...
Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults
WEDNESDAY, Nov. 20, 2024 – The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a November data brief published by the National...
About 1 in 10 U.S. Adults Have High Cholesterol
WEDNESDAY, Nov. 20, 2024 – Nearly 1 in every 10 American adults is living with high levels of cholesterol in their arteries, according to the latest report from the U.S. Centers for Disease Control...
Fish Oil Supplements Counteract Genetic Predisposition to High Cholesterol
WEDNESDAY, Aug. 14, 2024 – Fish oil seems to counteract genetic predisposition to high cholesterol, according to a study published online July 15 in the American Journal of Clinical Nutrition. ...
Fish Oil Might Help Keep Cholesterol in Check
THURSDAY, Aug. 8, 2024 – People with a genetic predisposition for high cholesterol can lower their levels by taking fish oil supplements, a new study shows. The results indicate that lifestyle can...
Plozasiran Reduces Triglyceride Levels in Mixed Hyperlipidemia
MONDAY, June 3, 2024 – For individuals with mixed hyperlipidemia, plozasiran reduces triglyceride levels at 24 weeks, according to a study published online May 28 in the New England Journal of...
U.S. FDA Approves Broad New Labels for Nexletol and Nexlizet to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) – Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for...
Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® ...
U.S. FDA Updates LDL-C Lowering Indication for Esperion’s Nexletol (bempedoic acid) Tablet and Nexlizet (bempedoic acid and ezetimibe) Tablet
Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA...
FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C)
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and...
FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
THOUSAND OAKS, Calif., Sept. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and ...
FDA Medwatch Alert: FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins
What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant...
FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) – Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an...
Further information
Related condition support groups
Related drug support groups
atorvastatin, Lipitor, simvastatin, Repatha, Crestor, pravastatin, Zetia, ezetimibe, rosuvastatin, Leqvio